Form 8-K - Current report:
SEC Accession No. 0001493152-23-033498
Filing Date
2023-09-22
Accepted
2023-09-22 17:25:10
Documents
14
Period of Report
2023-09-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50130
2 ex99-1.htm EX-99.1 15825
3 ex99-1_001.jpg GRAPHIC 15862
  Complete submission text file 0001493152-23-033498.txt   268970

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mtnb-20230921.xsd EX-101.SCH 3039
5 XBRL LABEL FILE mtnb-20230921_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mtnb-20230921_pre.xml EX-101.PRE 22375
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3312
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 231272527
SIC: 2834 Pharmaceutical Preparations